Mevion Medical Systems, Inc.

Mevion Medical Systems, Inc. offers a financially viable and technologically advanced solution in the proton therapy market for cancer treatment. Founded in 2004 as Still River Systems, the company was established to address the significant size and cost limitations of conventional proton therapy systems. A key figure in the company's development was former President and CEO Joseph Jachinowski, an executive with over 35 years in the medical device industry, who led the charge in creating the world's first compact proton therapy system. His background in electrical engineering and extensive experience at companies like Varian and as a co-founder of IMPAC Medical Systems provided a strong foundation for this endeavor.

The company's business model centers on the sale of its MEVION S250 Series proton therapy systems to hospital-based cancer centers, comprehensive cancer centers, and physician-owned clinics. By dramatically reducing the required capital investment and operational costs, Mevion makes this precise form of radiation therapy accessible to a broader range of healthcare providers. Since its initial funding round in 2005, the company has raised approximately $500 million, facilitating its growth and technological development. A significant milestone was achieved in 2012 when the MEVION S250 received FDA 510(k) clearance. The first patient treatment followed in 2013 at the Siteman Cancer Center.

Mevion's core product, the MEVION S250, is distinguished by its gantry-mounted superconducting synchrocyclotron, a design that significantly shrinks the system's footprint. The product line includes the MEVION S250i with HYPERSCAN pencil beam scanning for rapid and robust Intensity Modulated Proton Therapy (IMPT), and the MEVION S250-FIT, which is designed to be installed in a vault originally built for a conventional linear accelerator. This adaptability eliminates major construction costs for institutions looking to upgrade their capabilities. The company also offers scalable multi-room designs, the MEVION S250mx, to ensure continuous facility operation. Recent developments include the delivery of its first MEVION S250-FIT system to Stanford Health Care in early 2025.

Keywords: proton therapy systems, compact radiation therapy, cancer treatment technology, MEVION S250, pencil beam scanning, HYPERSCAN, gantry-mounted accelerator, single-room proton therapy, medical oncology devices, radiation oncology solutions, IMPT, Joseph Jachinowski, Still River Systems, cost-effective cancer care, advanced radiotherapy, particle therapy, oncology capital equipment, proton beam technology, cancer center equipment, hospital radiation therapy